Choose a language and wait for the translated text.
Sanofi will pay $1 billion upfront and up to $7 billion tied to development and regulatory milestones.. Both companies will share development and commercialisation costs, while profits from global sales will be shared on a 50:50 basis.
Sanofi bets up to $8 Bn on Regeneron’s Immunology pipeline in search for Dupixent successor | PharmaVoice
